Three-Time-Point PET Analysis of 68 Ga-FAPI-46 in a Variety of Cancers
Journal of Nuclear Medicine · 2023-04 · 64 (4) · 618-622
DOI: 10.2967/jnumed.122.264941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 10.11.2022. Verfasst von Mahnoosh Naeimi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Quinolines. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A growing family of 68Ga-fibroblast activation protein inhibitor (FAPI) PET probes has shown promise in imaging a variety of medical conditions. 68Ga-FAPI-46, in particular, has emerged as unique for both its diagnostic and its theranostic applications; however, the optimal timing of PET remains unclear. Therefore, we evaluated uptake at 3 time points after 68Ga-FAPI-46 administration in a spectrum of tumor types.
Methods
The cohort consisted of 43 patients with diverse cancer diagnoses undergoing 68Ga-FAPI-46 PET/CT at 3 time points (10 min, 1 h, and 3 h). We determined the tracer uptake based on SUVmean and SUVmax and on tumor-to-background-ratios (TBRs) (SUVmax/SUVmean).
Results
There were 171 lesions in the 43 patients. Comparing all lesions at different time points, the mean SUVmax was maximal at 10 min (8.2) and declined slightly at 1 h (8.15) and 3 h (7.6) after tracer administration. Similarly, the mean SUVmax log still had a similar pattern in primary lesions at 10 min, 1 h, and 3 h (n = 30; 0.98, 1.01, and 0.98, respectively), lymph node metastases (n = 37; 0.82, 0.84, and 0.81, respectively), and distant metastases (n = 104; 0.81, 0.79, and 0.74, respectively). TBR also showed nonsignificant differences at the 3 times.
Conclusion
68Ga-FAPI-46 PET/CT imaging revealed remarkably stable tumor and background uptake as determined by SUV metrics and maintained high TBRs within 3 h of injection. Thus, it may be possible to scan with 68Ga-FAPI-46 within 10-20 min of injection, improving workflow and decreasing patient wait times. Confirmation of these findings in a larger cohort is under way.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
- Department of Nuclear Medicine, Medical Faculty of Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany.
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany; and.
- Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; frederik.giesel@med.uni-duesseldorf.de.
Zitieren
APA
Naeimi, M., Choyke, P. L., Dendl, K., Mori, Y., Staudinger, F., Watabe, T., Koerber, S. A., Röhrich, M., Debus, J., Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2023). Three-Time-Point PET Analysis of 68 Ga-FAPI-46 in a Variety of Cancers. Journal of Nuclear Medicine, 64(4), 618-622. https://doi.org/10.2967/jnumed.122.264941
Vancouver
Naeimi M, Choyke PL, Dendl K, Mori Y, Staudinger F, Watabe T, et al. Three-Time-Point PET Analysis of 68 Ga-FAPI-46 in a Variety of Cancers. Journal of Nuclear Medicine. 2023;64(4):618-622. doi:10.2967/jnumed.122.264941
BibTeX
@article{Naeimi2023,
author = {Naeimi, Mahnoosh and Choyke, Peter L and Dendl, Katharina and Mori, Yuriko and Staudinger, Fabian and Watabe, Tadashi and Koerber, Stefan A and Röhrich, Manuel and Debus, Jürgen and Kratochwil, Clemens and Haberkorn, Uwe and Giesel, Frederik L},
title = {Three-Time-Point PET Analysis of 68 Ga-FAPI-46 in a Variety of Cancers},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {4},
pages = {618--622},
doi = {10.2967/jnumed.122.264941}
}
EUVIMED